logo
Confessions of a Former Nurx Addict

Confessions of a Former Nurx Addict

Yahoo4 hours ago

It was the beginning of 2019—I had been working at a new company for almost exactly a year, and I was super stressed about my healthcare situation. No, I didn't have any diseases or serious conditions. I wasn't sick or even worried about the possibility of getting sick (although that joke was on me; I caught COVID-19 four separate times in 2020). But for the first time in my life, I found myself in health insurance hell.
To be fair, dealing with any healthcare bureaucracy in America is sure to be frustrating and annoying, and will most likely turn into a Kafkaesque nightmare. But when you're 28 and still in the honeymoon phase of a new-ish relationship, an abrupt cut-off of your birth control—with no warning and no clear path to restart it—starts to feel less like a logistical hiccup and more like an existential crisis.
More from Flow Space
UPDATE: Your State-by-State Guide to Understanding Menopause Insurance Options
See, the OB-GYN I saw once a year was on vacation, then booked for the next seven months straight (not that she was in-network anyway), and WITH INSURANCE, the pharmacy was charging me over $130 for one pack, only one month's worth, of pills. The health insurance at my last two jobs had charged me $0 for birth control. In fact, at that point, I had been taking Lo Loestrin FE regularly for 12 years and had never once paid for it.
I was, as the kids say, shook.
Thankfully, in the midst trying to figure out what to do, I was in the kitchen with a couple of coworkers, when I overheard them mention Nurx. They were both raving about it, but I couldn't tell if it was a fancy boutique or a new dish at their favorite brunch spot—all I could tell was that they both thought Nurx was great.
I was having fun making wild guesses in my head, but I also. didn't want to miss out on something seemingly so delightful, so I finally asked them, 'What's Nurx?'
In retrospect, it's a little weird that both ladies were surprised I hadn't heard of it. Because, remember this took place pre-COVID and the ensuing telehealth boom.
In fact, in 2019, only 10% of Americans ever participated in a telehealth visit, according to a 2024 survey conducted by hims & hers; the most recent data shows a 440% rise in telehealth adoption with 54% having had a telehealth appointment as of early 2025.
While I might have been early to to the telemedicine game compared to the general public, I was late to Nurx, which launched in 2015, as far as my work friends were concerned. And they were right.
For the next four years, everything about my birth control was seamless. I paid $15 dollars for an initial consult (I believe that fee has gone up to $28 now for birth control patients), and by some incredible stroke of luck, the same afternoon I learned about Nurx, I received a company-wide email explaining that our health insurance plans were changing slightly. The notice didn't go into much detail other than that our copays would be going up—birth control costs definitely weren't mentioned—but I found out via chat with the Nurx team through their app that my medication cost would be $0. They would send me three packs at a time, refills were automatic and shipping was free.
Other than the initial $15, I would only have to pay a $3 service fee each month—meaning one full year of Lo Loestrin FE would come out to approximately $51. Just days prior, the same health insurance company wanted me to pay around $87 more for a single pack of medicine from a pharmacy where I'd have to remember to call in all my own refills, go pick them up every single month, wait in a never-ending line and then have some pharmacy tech tell me 'it's gonna be another 30 minutes,' despite the text on my phone announcing 'my prescription is ready for pick-up.'
In all honestly, I had become dependent on the impeccable consistency and convenience of Nurx. It felt like the company had truly taken a necessary task (managing your birth control) off your plate and put it on the the most dependable auto-pilot.
At the end of 2019, Nurx sent out an email recapping exciting things that had happened that year, and it mentioned how they had not only launched HPV home testing and STI home testing and treatment, but also how August 2019 marked one year of providing PrEP home test kits for HIV prevention. I remember at some point later down the line, the introduced some prescription skin products, but as long as my birth control was being taken care of, I really wasn't paying attention to Nurx. It was great!
Then, on March 20, 2023, I received a message from Nurx stating, 'Lo Loestrin Fe will no longer be stocked at our pharmacy. This means we cannot refill your birth control prescription.' But it went on to offer me options, Nurx could send my prescription to a local pharmacy or I could work with their medical team to find something similar to switch to.
Considering that I had noticeably (and quickly) gained weight on three different birth controls my OB-GYN had me try before we landed on Lo Loestrin Fe, the decision was a no-brainer. So I asked them to to send to my local pharmacy, and it was OK for the most part. I missed the convenience of getting my prescription shipped directly to my apartment and I could only get one pack at a time instead of three, but I couldn't really complain.
At least not until March 21, 2024. The only reason I know some of these exact dates is because I did complain; I complained via a 1,400-word email with certain sections highlighted yellow and other section written with pink or blue or orange. I utilized the 'bold' function more than was necessary. I must imagine that my email was the most colorful 'angry email' Nurx has ever received.
What happened? Well, the only thing that Nurx had figured out how to automate yet was the yearly renewal process. Once a year, you had to go onto their platform to manually renew your prescription. I had done exactly that on February 21, 2024 and immediately received a confirmation that my renewal went through; the next day, I got another message confirming that my prescription had been sent to my pharmacy.
I was able to pick up my first pack of birth control (of the 12-mont prescription) on March 21, 2024—but when I tried to put in the next month's refill, the pharmacy said they had no record of me or my Lo Loestrin FE in its system. When I reached out to Nurx, I was told they had already sent all remaining refills to my local pharmacy and suggested I speak to them, clearly forgetting that the pharmacy had insisted I get in touch with Nurx. It was a never-ending circle of not getting my birth control, yet continuing to pay a $3 service fee every month. I tried everything I could think of, but Nurx stopped responding to my messages, including my colorful monster-of an email. Despite the unfortunate ending of my time with Nurx, it was, without-a-doubt, it was still the best and easiest approach to birth control prescriptions that I've ever seen. After my March refill ran out and I was just beginning to step into my drama-filled exit with the telehealth platform, the pharmacist who was telling me I didn't exist in their system ended up giving me a free pack of Lo Loestrin FE. My former OB-GYN had moved away, and so I found a new doctor on ZocDoc and went back to relying on my yearly well-woman exam as a means to procure my birth control.
I wasn't overly fond of this physician so when I realized she had only prescribed me six months worth of Lo Loestrin Fe, I decided I wasn't even going to bother calling her office to ask for a refill. It was October 2024 at this point, living in a post-COVID world, I expected to find more than one freshly launched telehealth platform that would surely outrival Nurx.
After some research I chose to create an account with Pandia Health, a telehealth platform focused solely on women's hormonal care from birth control to hormone replacement therapy (HRT).
I knew that Nurx had been adding treatments here and there, but it wasn't until I started looking into new telehealth options that I realized it had evolved into far more than just a birth control platform. They now offer everything from Ozempic and Wegovy for weight management and prescription anti-aging skin care to minoxidil for women's hair loss and essential everyday care for core gynecological issues. But it's their mental health services that seem to have gained the most traction—now standing alongside birth control as one of Nurx's primary offerings.
I was surprised to find a number of online reviews comparing Nurx to Brightside Health, a subscription-based online psychiatry and therapy platform that I also happen to use; I started on Brightside in 2020 and remain a member to this day. I only have great things about my experience with Brightside but, for me, comparing the two is an apples-oranges situation.
And through writing this piece, it seems somewhat obvious to me that Nurx was going through some massive changes at the time of my issue with them. And considering how disastrous Pandia Health turned out to be—every single month you're expected to fill out and submit a form consenting to your prescription, and since it can take up to 10 days to arrive (if it ever actually does), you're constantly inundated with 'refill reminder' and 'refill consent confirmation reminder' emails—Nurx is still easily the best way I've ever received birth control. When it was working, it was the gold standard. I can only hope that any of the kinks I experienced were from its growth spurt into a fully fledged online clinic for women's health and that the shortcomings I encountered have all been worked out by now.
As for me, after Pandia failed to deliver my birth control twice, I stopped using them. I then embarked upon an exhaustive, all-night search for a platform that met, what I thought was, some simple criteria—it needed to either be cheap or take my insurance, carry Lo Loestrin FE, able to send three packs at the same time and actually send them to directly to me through the mail. I finally decided two out of four wasn't that bad. I signed up with an online medical consultation service called Dr.B, which was very simple and very cheap (a consultation is $15, then medication costs are handled by your insurance). But I had to have them send the prescription to a local New York pharmacy and I only get one pack at a time.
I thought after such a struggle, I was finally in OK place with my birth control. Do I have to physically drag myself to a pharmacy? Yes, but at least Dr.B doesn't clog up my inbox by sending emails every other day. I actually picked up my first packet of Lo Loestrin Fe placed through Dr.B last Friday. The pharmacist called to let me know it was ready and then said, 'Can you come pick it up ASAP? I told her I'd come in after work. She responded with, 'OK, like you really need to come get it though because we're closing down. Closing down for good.' 'When exactly?' I asked. Her answer? Monday.
So that's a new birth control thing to worry about. I'm honestly considering restarting my subscription with Nurx.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Incyte replaces CEO Hoppenot with dealmaker Meury
Incyte replaces CEO Hoppenot with dealmaker Meury

Yahoo

time28 minutes ago

  • Yahoo

Incyte replaces CEO Hoppenot with dealmaker Meury

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. Meury, whose appointment is effective immediately, previously ran Anthos Therapeutics, which he sold this year to Novartis for nearly $1 billion, and Karuna Therapeutics, which Bristol Myers Squibb bought for $14 billion in 2023. Prior to those posts, Meury was chief commercial officer at Allergan. Hoppenot will remain on Incyte's board of directors through the end of this year to aid Meury's transition into the CEO role. Alongside the succession, Julian Baker, managing partner of biotechnology investor Baker Bros. Advisors and lead independent director for Incyte, was elected board chair. Much of Hoppenot's time at Incyte focused on what he once described as 'single asset syndrome.' The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. Last year, Jakafi brought in nearly $2.8 billion in sales. But Jakafi's main patents expire in 2028, a date that for years now has been on investors' radar as they've pressed Incyte on what it expects will take the drug's place. Early in Hoppenot's tenure, the answer looked like a cancer medicine called epacadostat, which Incyte believed could become a cornerstone of immunotherapy combinations. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates. Since then, Incyte has had some success building out its portfolio. The company now owns six other approved drugs, including a cream formulation of Jakafi's main ingredient that's proved useful treating atopic dermatitis and vitiligo. 'Hervé joined Incyte in 2014 when it was a single product, U.S.-only company,' said board member Baker, in a statement. 'During Hervé's tenure, Incyte launched six novel medicines plus two new indications for Jakafi, expanded commercial operations into Europe, Japan and Canada and grew revenues from $355 million dollars in 2013 to $4.2 billion today.' However, Incyte's other drugs don't make it much money. Jakafi and the cream formulation of the drug Incyte sells as Opzelura accounted for 91% of net product revenues last year. (The company also earned nearly $600 million in royalty revenues.) Stephen Willey, an analyst at Stifel, gives Hoppenot credit for increasing Incyte revenues by more than 10 times during his time as CEO. But, in a Thursday note to clients, he added that some investors grew frustrated with the company's high research and development spending without a clear post-Jakafi plan. Shaping those plans will now fall to Meury, who gained industry visibility by guiding his prior two companies to lucrative acquisitions. 'We expect the immediate reaction from investors will be an expectation that [Incyte] could now become an M&A target, simply because Mr. Meury sold Anthos ... and sold [Karuna],' wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. Shares in Incyte, which have fallen by 30% over the past five years, rose by more than 4% in Thursday morning trading on the CEO news. 'It has been a privilege to lead Incyte over the past eleven years,' Hoppenot said in the company's statement. 'I am proud to retire at a time when Incyte has the strongest management team, internal R&D pipeline and commercial portfolio ever.' Incyte expects multiple pivotal trial readouts this year, along with proof-of-concept data for several pipeline candidates. Recommended Reading Unblinded: Hervé​ Hoppenot on solving Incyte's 'single asset syndrome' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture
After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture

CBS News

time36 minutes ago

  • CBS News

After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture

New medical technology being used to reduce the risk of repeat injuries suffered by athletes New medical technology being used to reduce the risk of repeat injuries suffered by athletes New medical technology being used to reduce the risk of repeat injuries suffered by athletes A new medical technology that acts like a seatbelt is aimed at reducing the risk of repeated knee injuries often suffered by athletes of all levels. Seventeen-year-old Nicholas Pohorilenko is ready to start practice after tearing his ACL almost two years ago. "Honestly, I thought my like sports career was over because a lot of people don't come back from that," Pohorilenko said. The tight end for Council Rock South High School said it happened when another player's helmet crashed into his knee. "I was able to jog off the field, and then I got to the sidelines and I like literally couldn't walk," he said, "It was horrible." The ACL –anterior cruciate ligament – is a vital structure in the knee. A tear or rupture requires surgery and a long rehab. "Our young athletes who, in general, have the highest rate of ACL injury also, unfortunately, come with the highest rates of re-rupture," said Dr. Sommer Hammoud with Rothman Orthopaedics. Dr. Hammoud is using new technology to reduce the risk of a potential re-rupture. She said it's like a seatbelt that's surgically implanted with the graft, which is used to repair the ACL. It prevents the graft from being overstretched, acting like an internal brace. Arthrex "I think this is the simplest thing that one can add to a ligament repair or reconstruction that is likely gonna have a huge potential benefit to the patient," said Dr. Hammoud. Pohorilenko said the rehab was long and difficult, but he's happy he has the so-called seatbelt in his repaired knee. "I think it's great, like, cause you people tear their ACLs multiple, multiple times," he said. "With this, tear it once, you get this technology and you're done." Best of all, his knee is fine and he'll be back playing the game he loves for his senior season. Since the technology is relatively new, doctors don't know yet exactly how much it will reduce re-ruptures of the ACL. CBS Philadelphia

Angels manager Ron Washington to miss rest of season with unspecified medical issue
Angels manager Ron Washington to miss rest of season with unspecified medical issue

Washington Post

time38 minutes ago

  • Washington Post

Angels manager Ron Washington to miss rest of season with unspecified medical issue

ANAHEIM, Calif. — Los Angeles Angels manager Ron Washington will miss the rest of the season because of an unspecified medical issue, the team said Friday. Washington, the oldest manager in the major leagues at 73, has been sidelined for the past week. He experienced shortness of breath and appeared fatigued toward the end of a four-game series at the New York Yankees that ended on June 19. He flew back to Southern California, underwent a series of tests and was placed on medical leave.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store